Unicycive Therapeutics (UNCY) Debt to Equity (2020 - 2024)
Unicycive Therapeutics posted quarterly Debt to Equity of -$0.01 for Q1 2024, up 100.0% on a QoQ basis from -$521.01 in Q2 2023.
Unicycive Therapeutics (UNCY) has 4 years of Debt to Equity data on file, last reported at -$0.01 in Q1 2024.
- For the quarter ending Q1 2024, Debt to Equity changed N/A year-over-year to -$0.01; the trailing twelve-month figure through Mar 2024 stood at -$0.01 (changed N/A YoY), and the FY2020 full-year result was -$0.36, changed N/A from the prior year.
- Debt to Equity for Q1 2024 stood at -$0.01, up from -$521.01 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.01 in Q3 2021 and bottomed at -$521.01 in Q2 2023.
- The 4-year median for Debt to Equity is -$0.21 (2021), against an average of -$104.32.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.06 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -0.01 |
| Jun 30, 2023 | -521.01 |
| Sep 30, 2021 | 0.01 |
| Jun 30, 2021 | -0.21 |
| Dec 31, 2020 | -0.36 |